METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009865 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Ling Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Shunde Hospital of Southern Medical University, Foshan, Guangdong, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immunotherapy, Methyltransferases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Guangdong Province, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Although immune checkpoint blockade (ICB) therapy represents a bright spot in antitumor immunotherapy, its clinical benefits in colorectal cancer (CRC) are limited. Therefore, a new target for mediating CRC immunosuppression is urgently needed. Adenomatous polyposis coli (APC) mutations have been reported as early-stage characteristic events in CRC, but the role of truncated APC in the CRC immune microenvironment remains unclear and its clinical significance has yet to be explored.
Design
Adenocarcinoma formation in the colon of the APC Min/+ mouse model, which displays features associated with the translation of truncated APC proteins, was induced by azoxymethane/dextran sodium sulfate. Multiplexed immunohistochemical consecutive staining on single slides and flow cytometry were used to explore the activation of immune cells and the expression of the immune checkpoint V-domain immunoglobulin suppressor of T-cell activation (VISTA) in the CRC tissues of APC WT and APC Min/+ mice. The construction of truncated APC vectors and an initial subserosal graft tumor mouse model was employed to mimic the tumor microenvironment (TME) during APC mutation. Methylated RNA immunoprecipitation-quantitative PCR assays were performed to investigate the N6-methyladenosine (m6A)-dependent transcriptional regulation of hypoxia-inducible factor-1 alpha (HIF1α) by methyltransferase-like protein 3 (METTL3). Mettl3 fl/fl vil1-cre +/− mice were used to demonstrate that targeting METTL3 is a mediator that mitigates the deleterious effects of the APC978∆-HIF1α axis on antitumor immunity. A chimeric VISTA humanized mouse model was used to evaluate the drug efficacy of the VISTA-targeted compound onvatilimab.
Results
We showed that APC978∆, a truncated APC protein, mediated overexpression of METTL3, resulting in m6A methylation of HIF1α messenger RNA and high expression of HIF1α. Furthermore, HIF1α promotes the migration of myeloid-derived suppressor cells to the TME by binding to the promoters of MCP-1 and MIF. In addition, HIF1α enhances the expression of the immune checkpoint VISTA on CRC cells, weakening tumor immune monitoring.
Conclusions
We elucidate that an underappreciated function of truncated APC in CRC is its ability to drive an immunosuppressive program that boosts tumor progression. Our work could provide a new perspective for the clinical application of immunotherapy in patients with CRC resistant to ICB therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Shunde Hospital of Southern Medical University, Foshan, Guangdong, China.
- Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Medical Oncology, Guangzhou Medical University Affiliated Cancer Hospital, Guangzhou, Guangdong, China.
- Department of Pathology, Shunde Hospital of Southern Medical University, Foshan, Guangdong, China liangsmu@foxmail.com.
ORCID-Profile: Liang Zhao
Förderung
- Natural Science Foundation of Guangdong Province
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Guangzhou Municipality
Zitieren
APA
Wu, L., Bai, R., Zhang, Y., Chen, H., Wu, J., Chen, Z., Wang, H., & Zhao, L. (2024). METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009865
Vancouver
Wu L, Bai R, Zhang Y, Chen H, Wu J, Chen Z, et al. METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009865
BibTeX
@article{Wu2024,
author = {Wu, Ling and Bai, Rui and Zhang, Yujie and Chen, Hao and Wu, Jianghua and Chen, Zetao and Wang, Hui and Zhao, Liang},
title = {METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009865}
}
EUVIMED